Published in PLoS One on September 04, 2008
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92
Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol (2010) 1.81
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol (2009) 1.55
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci (2015) 1.52
Inhibition of amyloid-β plaque formation by α-synuclein. Nat Med (2015) 1.52
Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol (2008) 1.29
Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol (2009) 1.27
Calcium signaling in neurodegeneration. Mol Neurodegener (2009) 1.27
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathol (2013) 1.15
Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med (2010) 1.13
Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog (2013) 1.10
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Front Aging Neurosci (2014) 1.09
ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther (2014) 1.08
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
α-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci (2011) 1.04
Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein. J Biol Chem (2011) 1.04
Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur J Neurosci (2010) 1.01
AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging (2011) 0.98
Role of synucleins in Alzheimer's disease. Neurotox Res (2009) 0.98
Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets (2009) 0.98
α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2013) 0.96
Autophagy in dementias. Brain Pathol (2012) 0.95
An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain. Front Physiol (2012) 0.93
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One (2010) 0.93
Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry (2014) 0.93
Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J (2012) 0.93
α-synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol Neurodegener (2010) 0.93
Cell-to-cell transmission of α-synuclein aggregates. Methods Mol Biol (2012) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
PESCADOR, a web-based tool to assist text-mining of biointeractions extracted from PubMed queries. BMC Bioinformatics (2011) 0.90
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics (2016) 0.90
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Prion strain interactions are highly selective. J Neurosci (2010) 0.87
Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther (2012) 0.87
In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy. J Neurosci (2012) 0.87
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology (2011) 0.87
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
New α- and γ-synuclein immunopathological lesions in human brain. Acta Neuropathol Commun (2014) 0.85
Dopamine-induced α-synuclein oligomers show self- and cross-propagation properties. Protein Sci (2014) 0.85
Assessing the causes and consequences of co-polymerization in amyloid formation. Prion (2013) 0.83
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Mol Neurodegener (2014) 0.82
Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation. J Alzheimers Dis (2014) 0.82
Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Mov Disord (2015) 0.81
CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease? Ann Clin Transl Neurol (2014) 0.80
Insights into the consequences of co-polymerisation in the early stages of IAPP and Aβ peptide assembly from mass spectrometry. Analyst (2015) 0.79
Cross-interactions between the Alzheimer Disease Amyloid-β Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis. J Biol Chem (2016) 0.79
Retracted β-Amyloid and α-synuclein cooperate to block SNARE-dependent vesicle fusion. Biochemistry (2015) 0.79
Integrative analysis of common neurodegenerative diseases using gene association, interaction networks and mRNA expression data. AMIA Jt Summits Transl Sci Proc (2012) 0.79
Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions. ACS Chem Neurosci (2015) 0.78
Cross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study. PLoS One (2014) 0.77
α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol (2016) 0.77
Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs. Microb Cell (2016) 0.77
Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci (2016) 0.76
Prion infection promotes extensive accumulation of α-synuclein in aged human α-synuclein transgenic mice. Prion (2012) 0.76
The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction. J Neurol (2011) 0.76
Amylin-Aβ oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer's disease. Phys Chem Chem Phys (2016) 0.76
Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease. Proc Natl Acad Sci U S A (2016) 0.75
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP. PLoS One (2017) 0.75
The amyloid interactome: Exploring protein aggregation. PLoS One (2017) 0.75
What we can learn from animal models about cerebral multi-morbidity. Alzheimers Res Ther (2015) 0.75
First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord (2016) 0.75
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A (2017) 0.75
Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol (2017) 0.75
Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. Mol Neurobiol (2016) 0.75
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias. Curr Neurol Neurosci Rep (2017) 0.75
MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging (2017) 0.75
Lipid rafts and signal transduction. Nat Rev Mol Cell Biol (2000) 25.87
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
Lipid rafts: elusive or illusive? Cell (2003) 7.99
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science (2001) 5.45
Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord (2001) 5.09
Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci (2001) 4.92
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol (2001) 4.27
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A (2005) 3.91
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem (2004) 3.87
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Protein docking using spherical polar Fourier correlations. Proteins (2000) 3.60
Constant pressure and temperature molecular dynamics simulation of a fully hydrated liquid crystal phase dipalmitoylphosphatidylcholine bilayer. Biophys J (1995) 3.41
Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci (2007) 3.16
Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A (1993) 3.16
Emerging themes in lipid rafts and caveolae. Cell (2001) 3.09
Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J (2001) 3.08
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96
Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med (1997) 2.95
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol (2002) 2.92
Calcium and neurodegeneration. Aging Cell (2007) 2.90
Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell (1993) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci (2004) 2.65
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans (2002) 2.55
Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem (2001) 2.49
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis (2006) 2.41
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry (2002) 2.29
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
The aggregation and fibrillation of alpha-synuclein. Acc Chem Res (2006) 2.17
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A (2004) 2.13
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron (2001) 2.05
Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res (2001) 2.04
The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet (1995) 2.03
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry (2002) 1.98
The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem (2003) 1.97
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol (1998) 1.89
Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging (2004) 1.88
Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis (2006) 1.83
Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol (2003) 1.81
Lipid rafts in health and disease. Biol Cell (2007) 1.81
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Role of the beta-amyloid protein in Alzheimer's disease. FASEB J (1995) 1.75
The neuropathogenic contributions of lysosomal dysfunction. J Neurochem (2002) 1.72
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63
A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem (2005) 1.60
Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol (2007) 1.54
Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci U S A (1996) 1.49
Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med (2003) 1.46
Docking essential dynamics eigenstructures. Proteins (2005) 1.45
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
Membrane binding and self-association of alpha-synucleins. Biochemistry (2001) 1.41
Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem (2005) 1.41
Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res (1998) 1.38
Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J (2007) 1.35
NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A (1995) 1.32
Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol (2004) 1.30
Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem (2001) 1.29
Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J Biol Chem (1996) 1.29
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry (2003) 1.27
Helical alpha-synuclein forms highly conductive ion channels. Biochemistry (2007) 1.24
Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J (2007) 1.24
The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther (2004) 1.24
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (2006) 1.19
Abeta42-peptide assembly on lipid bilayers. J Mol Biol (2002) 1.18
Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. Biochemistry (2008) 1.18
Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem (2006) 1.17
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry (2005) 1.16
Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem (2001) 1.12
Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin (2000) 1.11
An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther (2004) 1.10
ADDLs & protofibrils--the missing links? Neurobiol Aging (2002) 1.10
Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation. J Neuroimmune Pharmacol (2008) 1.09
Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J (1997) 1.09
Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl (1998) 1.08
Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem (2006) 1.07
Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl (2002) 1.06
Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord (2006) 1.06
Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol (2006) 1.05
Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. J Neurochem (2006) 1.02
Structural determinants of the Alzheimer's amyloid beta-peptide. J Neurochem (1994) 0.98
Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol (2006) 0.97
Aggregation and fibrillization of prions in lipid membranes. Biochem Soc Symp (2005) 0.95
Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res (2000) 0.94
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature (2005) 9.44
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature (2006) 4.54
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2004) 2.79
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 2.75
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem (2010) 2.67
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A (2004) 2.55
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol (2004) 2.37
Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med (2003) 2.36
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol (2010) 2.29
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Inhibition of endogenous TRP1 decreases capacitative Ca2+ entry and attenuates pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol (2002) 2.13
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med (2012) 2.07
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron (2003) 2.02
Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest (2009) 2.02
Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92
PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol (2003) 1.91
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87